Expression of carbonic anhydrase IX in human pancreatic cancer
Authors:
- 19 September 2003
- journal article
- website
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 18 (8) , 837-846
Abstract
Summary: Background : Carbonic anhydrase IX has been linked to cancer development and progression.Aim : To analyse carbonic anhydrase IX expression and anhydrase inhibition in pancreatic cancer and to correlate these findings with p53 expression and microvessel density.Materials and methods : Seventy‐seven pancreatic cancers were examined (43 males, 34 females; mean age, 64 years). The anti‐carbonic anhydrase IX M75 antibody was used for immunohistochemistry and Western blot analysis. Microvessels were visualized using the anti‐CD34 antibody, and p53 expression in cancer cells was assessed with a specific anti‐p53 antibody. Quantitative polymerase chain reaction was performed in order to assess carbonic anhydrase IX mRNA levels in the pancreas. Furthermore, pancreatic cancer cell lines were treated with acetazolamide, a carbonic anhydrase inhibitor.Results : In the normal pancreas, carbonic anhydrase IX immunoreactivity was observed at the basolateral membrane of ductal cells in 24 cases (31%). Carbonic anhydrase IX expression was found at the membrane and in the cytoplasm of pancreatic cancer cells in 16 pancreatic cancers (21%). Carbonic anhydrase IX expression was independent of the localization, stage, size, metastases and differentiation of the tumour. p53 expression was significantly more frequent in poorly differentiated cancers (P = 0.0323); however, p53 expression and microvessel density were independent of carbonic anhydrase IX expression. Overall, carbonic anhydrase IX expression was not altered in pancreatic cancers vs. adjacent normal pancreatic tissue as assessed by Western blot and quantitative polymerase chain reaction analysis. However, incubation of pancreatic cancer cell lines with acetazolamide led to a significant inhibition of cell proliferation in AsPC‐1 and PANC‐1 pancreatic cancer cells.Conclusion : Carbonic anhydrase IX expression is observed in both ductal epithelial and cancer cells of the pancreas. Although the expression of carbonic anhydrase IX in pancreatic cancer is not associated with angiogenesis or advanced disease, it may well be a target for carbo‐anhydrase inhibitors in a subset of pancreatic cancers.Keywords
This publication has 28 references indexed in Scilit:
- Implications of growth factor alterations in the treatment of pancreatic cancerMolecular Cancer, 2003
- MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomasBritish Journal of Cancer, 1999
- Carbonic Anhydrase in Human Pancreas: Hypotheses for the Pathophysiological Roles of CA IsozymesAnnals of the New York Academy of Sciences, 1999
- MN/CA9 gene expression as a potential biomarker in renal cell carcinomaBJU International, 1999
- Immunohistochemical Study of Colorectal Tumors for Expression of a Novel Transmembrane Carbonic Anhydrase, MN/CA IX, with Potential Value as a Marker of Cell ProliferationThe American Journal of Pathology, 1998
- Immunohistochemistry of Carbonic Anhydrase Isozyme IX (MN/CA IX) in Human Gut Reveals Polarized Expression in the Epithelial Cells with the Highest Proliferative CapacityJournal of Histochemistry & Cytochemistry, 1998
- MN antigen expression in normal, preneoplastic, and neoplastic esophagus: A clinicopathological study of a new cancer-associated biomarkerHuman Pathology, 1997
- Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tractsGastroenterology, 1997
- A Study of Biomarkers in Cervical Carcinoma and Clinical Correlation of the Novel Biomarker MNGynecologic Oncology, 1996
- Expression of MaTu‐MN protein in human tumor cultures and in clinical specimensInternational Journal of Cancer, 1993